Pell Bio-Med Technology Co., Ltd.
6949
Rank in Stocks
#6322
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in... Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.
Share Price
$1.37
Last synced: 2026-11-13
Market Cap
$1.79B
Change (1 day)
9.67%
Change (1 year)
-88.92%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pell Bio-Med Technology Co., Ltd. (6949)
Category
Healthcare
Operating Margin for Pell Bio-Med Technology Co., Ltd. (6949)
Operating Margin as of November 2026 TTM: -1,463.15%
According to Pell Bio-Med Technology Co., Ltd.'s latest financial reports, its current operating margin (TTM) is -1,463.15%. At the end of 2025 the company had an operating margin of -1,487.24%.
Operating Margin history for Pell Bio-Med Technology Co., Ltd. from 2021 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,463.15% | -1.62% |
| 2025 | -1,487.24% | -29.39% |
| 2024 | -2,106.35% | -7.64% |
| 2023 | -2,280.52% | 65.71% |
| 2022 | -1,376.17% | -1.84% |
| 2021 | -1,402.03% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -99.87% |
US
|
|
| 33.87% | -100.02% |
US
|
|
| -116.04% | -99.92% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pell Bio-Med Technology Co., Ltd.'s operating margin
What is Pell Bio-Med Technology Co., Ltd.'s operating margin?
Pell Bio-Med Technology Co., Ltd.'s operating margin is -1,463.15%, as of Nov 2026.
What was Pell Bio-Med Technology Co., Ltd.'s operating margin in 2025?
In 2025, Pell Bio-Med Technology Co., Ltd.'s operating margin was -1,487.24%, compared with -2,106.35% in 2024.
How has Pell Bio-Med Technology Co., Ltd.'s operating margin changed since 2021?
From 2021 to 2025, Pell Bio-Med Technology Co., Ltd.'s operating margin was highest in 2022 (-1,376.17%) and lowest in 2023 (-2,280.52%).
How does Pell Bio-Med Technology Co., Ltd.'s operating margin compare with similar companies?
Pell Bio-Med Technology Co., Ltd.'s operating margin (-1,463.15%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.